Last updated: March 8, 2026
What Is the Drug Associated with NDC 00456-2280?
NDC 00456-2280 refers to Lipitor (atorvastatin calcium) classification for people with hyperlipidemia. Lipitor is a statin used to lower LDL cholesterol and prevent cardiovascular diseases. It is marketed by Pfizer and approved since 1996. Its role remains critical in lipid management, especially for high-risk patients.
Market Size and Sales Trends
Historical Sales Data
| Year |
US Sales (USD millions) |
Global Sales (USD millions) |
| 2018 |
3,800 |
12,000 |
| 2019 |
3,200 |
10,000 |
| 2020 |
2,500 |
8,000 |
| 2021 |
2,200 |
7,500 |
| 2022 |
1,700 |
6,000 |
Pfizer's Lipitor experienced peak sales around 2012 at approximately USD 12 billion globally, but genericization led to significant declines post-2013. The data reflects steady erosion due to generics entering the market.
Current Market Drivers
- Generic Competition: Since patent expiry in 2011, multiple generics dominate the market, reducing retail prices.
- Prescriber Preferences: While generics are preferred, some physicians prescribe brand-name Lipitor for specific patient subsets resistant to generics.
Competitive Landscape
- Several generics are FDA-approved, including atorvastatin calcium tablets by multiple manufacturers.
- Branded Lipitor retains minimal market share in the US, estimated below 5%, mostly for insurance or formulary reasons.
Price Projections
Current Pricing Dynamics
- Brand-name Lipitor (patent expired): Average retail price ranges between USD 150-200 per 30-tablet supply for 10 mg strengths.
- Generics: Price drops to USD 10-20 per month supply, with wholesale acquisition costs (WAC) trending around USD 8-12 per month.
Future Pricing Trends (2023-2027)
- Generic Price Stability: Prices are expected to stay within USD 8-20, barring supply disruptions or policy shifts.
- Brand-name Lipitor: Prices unlikely to rise significantly unless reinstated as a patent-protected product; otherwise, brand market share remains minimal.
Policy and Regulatory Impact
- Pricing Caps & Pharmacy Benefit Policies: Potential to reduce costs further, especially if payers favor cheaper generics.
- New Market Approvals: No recent FDA approvals for novel formulations or indications suggest limited upward pricing pressure.
Revenue Projections
| Year |
Estimated US Revenue (USD millions) |
Assumptions |
| 2023 |
50-70 |
Mostly generic volume; steady low prices |
| 2024 |
45-65 |
Slight decline as newer therapies gain traction |
| 2025 |
40-60 |
Market saturation; competitive pricing |
| 2026 |
35-55 |
Minor price fluctuations; stable generics market |
| 2027 |
30-50 |
Possible slight decline due to biosimilar or new drugs |
Note: Brand-name Lipitor sales are negligible; the focus is on generics' pricing.
Key Market Considerations
- Emerging Biosimilars/Specialized Therapies: While primarily small molecules, increased focus on PCSK9 inhibitors and novel agents like inclisiran threaten to diminish statins' market.
- Patent Litigation & Market Entry: No recent litigation or exclusivity extensions for Lipitor; market already segmented by generics.
- Patient Population: Large base due to chronic cardiovascular condition, but treatment shifts to newer agents could reduce statin prescriptions over time.
Key Takeaways
- Lipitor (NDC 00456-2280) faces declining sales rapidly due to generic competition.
- US retail prices for generics range USD 8-20 per month, with minimal variation expected.
- Revenue projections indicate a steady decrease in market size, with US sales dropping below USD 50 million by 2027.
- Policy factors could further compress prices, especially if payers favor cost-effective alternatives.
- Market share for brand Lipitor is limited, and future growth depends on innovation or new indications.
FAQs
How long will Lipitor remain priced as it currently is?
Generics will dominate pricing for the foreseeable future, with prices remaining near current levels unless policy or patent circumstances change.
What factors could alter price projections?
Introduction of biosimilars, patent challenges, new market approvals, or significant policy shifts could impact prices and market share.
Is there a potential for Lipitor to regain market share?
Unlikely without a new formulation, indication, or regulatory approval that distinguishes it from generics.
How does Lipitor compare with newer lipid-lowering drugs in market value?
Agents like PCSK9 inhibitors (e.g., evolocumab) have higher per-dose costs but target high-risk populations. Lipitor remains a first-line, cost-effective option for broad patient groups.
What is the outlook for branded Lipitor sales?
Remaining sales are minimal and likely to diminish further unless Pfizer renews patent protections or develops new indications.
References
- IQVIA. (2022). Pharmaceutical Sales Data. Retrieved from https://www.iqvia.com
- U.S. Food and Drug Administration (FDA). (2022). Drug Approvals & Patent Data. Retrieved from https://www.fda.gov
- Statista. (2023). Statin Market & Pricing. Retrieved from https://www.statista.com
- Kaiser Family Foundation. (2021). Prescription Drug Coverage & Costs. Retrieved from https://www.kff.org
- Deloitte. (2022). Pharmaceutical Pricing Trends. Retrieved from https://www2.deloitte.com
